Industry News

Tobira Therapeutics, Inc. today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Monday, July 25 to discuss Phase 2 b results for cenicriviroc in patients with non-alcoholic steatohepatitis and liver fibrosis. A webcast replay will be available on the Tobira website for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 859-2056 for domestic..."/>
Tobira Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss CENTAUR Phase 2b Trial Results
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 and MN-002 for the treatment of“ fibrosis” which includes a broad range of fibrosis/ fibrotic disease in different organs due to different causes.. Once issued, the patent..."/>
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis
Kite Pharma: founder and CEO Arie Belldegrun, director and TPG founding partner David Bonderman, and director and Two River cofounder and managing director Joshua Kazam. Following the announcement, DNA..."/>
Israeli drug developer Entera Bio raises $7.5m [Globes, Tel Aviv, Israel]
Humana Inc. by Aetna Inc. and a $54 billion deal in which Anthem Inc. would buy Cigna Corp.."/>
Aetna, Cigna Futures Foggy In Wake Of Justice Department Decisions To Block Deals [The Hartford Courant]
Centene Corp., which plans to add more than 1..."/>
Is Clayton emerging as the St. Louis region's new 'downtown'? [St. Louis Post-Dispatch]
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’ s disease, other central nervous system diseases, pain and various types of cancer, today announced..."/>
Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
Cigna, the state Insurance Department is continuing its review of the proposal. "The two proceedings are completely separate," said Insurance Department attorney Jennifer Patterson. "So the fact that this lawsuit has been filed doesn't take away the commissioner's authority to hold a hearing and act on the matter."/>
Federal lawsuit won't stop state review of Anthem-Cigna merger [The New Hampshire Union Leader, Manchester]
Ameriprise Financial, fell 57 percent to $41.8 million, because he only exercised $18.1 million in stock options. In the previous two years, he made a total of $150 million by cashing in long-held options."/>
Total compensation for Minnesota public company leaders declines 19 percent [Star Tribune (Minneapolis)]
Biocon Ltd on Friday said it plans to launch recombinant human- insulin and long-acting insulin glargine in Malaysia in the second half of this financial year, after it received regulatory approval from the South-East Asian nation. According to Biocon, the insulin market in Malaysia is pegged at around $40 million including sales from tenders and retail. The Malaysian approval comes months after Japanese approval for Biocon's insulin glargine, providing a..."/>
Biocon to launch two insulin variants in Malaysia in fiscal 2017 [Mint, New Delhi]
Centene Corp. has been selected to provide managed care support to the Department of Defense Tricare program across 21 western states starting in 2017.."/>
UnitedHealthcare losing big military health contract [Star Tribune (Minneapolis)]
Spectranetics Corp. won a year ago against the cofounder of a company the Colorado Springs-based medical device manufacturer bought in 2014, ruling a federal court in California lacked jurisdiction to hear the case. Court of Appeals for the Federal Circuit in Washington, D.C., reversed the damage award ruling by a federal district court in San Francisco that Eitan Konstantino, the former cofounder, officer..."/>
Colorado Springs-based Spectranetics loses judgment in federal court [The Gazette (Colorado Springs, Colo.)]
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that its Board of Directors has authorized a plan to proceed with a consolidation of its outstanding common shares on the basis of ten pre-consolidation Shares for one post-consolidation Share. Currently, a total of 67,261,629 Shares are issued and outstanding. Accordingly, if the..."/>
RepliCel Life Sciences Continues Restructuring With Share Structure Consolidation
Shire Plc, the company said. Chronos has acquired all intellectual property, know-how, development and marketing rights for each programme on a worldwide basis. Shire becomes a strategic equity investor in Chronos and is eligible for milestone payments on regulatory approval of products..."/>
UK Biotech Firm Chronos Therapeutics Acquires 3 Pre-Clinical Programmes from Shire
XBiotech Inc., developer of next-generation True Human™ antibody therapies, said today that the Independent Data Monitoring Committee for the XCITE Phase III clinical study of Xilonix™ for the treatment of colorectal cancer, recently recommended study continuation without any amendment to the study design. The DMC convened as scheduled, subsequent to the enrollment of 400 patients into the study.. The DMC mandate is to“ monitor for early evidence of..."/>
XBiotech Provides Update on Xilonix™ Phase III Programs in US and EU
Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has adjusted the subscription price and related pricing information for its previously announced rights offering. The subscription pricing is now $4.10 per unit. The subscription period for the rights offering commenced on July 8, 2016, and the subscription rights will..."/>
Onconova Adjusts Pricing of Rights Offering

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials568 Articles
Consumer Discretionary513 Articles
Information Technology479 Articles
Industrials385 Articles
Health Care293 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at